About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
P
Optimizing the Management of Patients with Polycythemia Vera (PV)
By
Incyte
FEATURING
Prithviraj Bose
,
Raajit Rampal
By
Incyte
FEATURING
Prithviraj Bose
,
Raajit Rampal
73 views
October 10, 2024
© 2024, Incyte. MAT-JAK-05254 10/24
Comments are disabled for this content.
Featured Video
15:43
Incyte
Importance of Early Management of Patients with Myelofibrosis (MF)
Feat.
P. Bose,
R. Rampal
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
24:27
BMFcases
Experts Discuss Pros and Cons of Treatment Approaches in PV
Feat.
T. Bat,
A. Tefferi
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
22:21
Integrity CE
2024 Updates on Myeloproliferative Neoplasms, PV, and ET
Feat.
A. Tefferi
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
17:05
BMFcases
Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…
Feat.
T. Bat,
A. Tefferi
14:01
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
Feat.
M. Gomes da Silva
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
06:18
Cleveland Clinic Taussig Cancer Institute
SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…
Feat.
A. Gerds
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
24:48
Indy Hematology Review
2024 Updates on Myelofibrosis and Systemic Mastocytosis
Feat.
R. Rampal
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
18:42
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
Feat.
A. Goldberg
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
08:49
BMFcases
Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…
Feat.
T. Bat,
A. Tefferi
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
14:01
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Pediatric HLH: Terminology and Diagnosis
Feat.
E. Yilmaz Keskin
